Immunohistochemical localisation of advanced glycation end products in pulmonary fibrosis.

AIM: To investigate the presence and distribution of advanced glycation end products (AGE) in pulmonary fibrosis. METHODS: Lung tissue samples obtained from seven necropsy cases with idiopathic pulmonary fibrosis and seven with normal pulmonary parenchyma were examined immunohistochemically with a monoclonal antibody specific for AGE: 6D12. We also tested three cases with diffuse alveolar damage. RESULTS: All the specimens from cases with pulmonary fibrosis and diffuse alveolar damage showed strong AGE expression on macrophages. Lung specimens from normal parenchyma showed positive AGE immunoreactivity on macrophages from only two of seven cases. CONCLUSIONS: These findings suggest that AGE modified proteins accumulate in alveolar macrophages in patients with diffuse alveolar damage and idiopathic pulmonary fibrosis.

[1]  J. Baynes.  Role of Oxidative Stress in Development of Complications in Diabetes , 1991, Diabetes.

[2]  J. Kelley.  Cytokines of the lung. , 1992, The American review of respiratory disease.

[3]  R. Bucala,et al.  Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. , 1993, The American journal of pathology.

[4]  S. Kuwajima,et al.  Immunochemical Detection of Advanced Glycation End Products in Lens Crystallins From Streptozocin-Induced Diabetic Rat , 1993, Diabetes.

[5]  Gary R. Grotendorst,et al.  Exaggerated spontaneous release of platelet-derived growth factor by alveolar macrophages from patients with idiopathic pulmonary fibrosis. , 1987, The New England journal of medicine.

[6]  S. Phan,et al.  Cytokines and pulmonary fibrosis. , 1996, Biological signals.

[7]  K. Manogue,et al.  Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. , 1988, Science.

[8]  H. Sano,et al.  Hydroxyl Radical Mediates Nϵ-(Carboxymethyl)lysine Formation from Amadori Product , 1997 .

[9]  Y. Ouchi,et al.  Expression of immunoreactive activin A protein in remodeling lesions associated with interstitial pulmonary fibrosis. , 1996, The American journal of pathology.

[10]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[11]  S. Horiuchi.  Advanced Glycation End Products (AGE)-Modified Proteins and Their Potential Relevance to Atherosclerosis. , 1996, Trends in cardiovascular medicine.

[12]  T. Sasaki,et al.  Induction of macrophage growth by advanced glycation end products of the Maillard reaction. , 1994, Journal of immunology.

[13]  S. Ogawa,et al.  Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Kodama,et al.  Macrophage scavenger receptor mediates the endocytic uptake and degradation of advanced glycation end products of the Maillard reaction. , 1995, European journal of biochemistry.

[15]  Y. Morino,et al.  Immunochemical approach to characterize advanced glycation end products of the Maillard reaction. Evidence for the presence of a common structure. , 1991, The Journal of biological chemistry.

[16]  L. Maillard,et al.  Action des acides amines sur les sucres : formation des melanoidines par voie methodique , 1912 .

[17]  N. Taniguchi,et al.  beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. , 1993, The Journal of clinical investigation.

[18]  S. Horiuchi,et al.  Advanced Glycation End Products of the Maillard Reaction in Aortic Pepsin-Insoluble and Pepsin-Soluble Collagen From Diabetic Rats , 1996, Diabetes.

[19]  R. Crystal,et al.  Alveolar macrophages release an insulin-like growth factor I-type molecule. , 1988, The Journal of clinical investigation.

[20]  T. Kodama,et al.  Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta with a novel specific monoclonal antibody. , 1995, The American journal of pathology.

[21]  A. Cerami,et al.  Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. , 1988, The New England journal of medicine.

[22]  A. Cerami,et al.  Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors , 1986, The Journal of experimental medicine.

[23]  K. O. Elliston,et al.  Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. , 1992, The Journal of biological chemistry.

[24]  池田和義.  N[ε]-(Carboxymethyl)lysine Protein Adduct Is a Major Immunological Epitope in Proteins Modified with Advanced Glycation End Products of the Maillard Reaction(カルボキシメチルリジン付加体はメイラード反応後期生成物の主要エピトープある) , 1997 .

[25]  S. Kuwajima,et al.  Immunochemical Detection of Advanced Glycation End Products in Renal Cortex From STZ-Induced Diabetic Rat , 1993, Diabetes.

[26]  V. Monnier,et al.  Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Martina,et al.  Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins. , 1992, The Journal of clinical investigation.

[28]  Y. Morino,et al.  Immunochemical evidence for the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. , 1992, The Journal of biological chemistry.

[29]  Yukiko Kurihara,et al.  A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection , 1997, Nature.

[30]  A. Schmidt,et al.  Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[31]  H. Sano,et al.  N (epsilon)-(carboxymethyl)lysine protein adduct is a major immunological epitope in proteins modified with advanced glycation end products of the Maillard reaction. , 1996, Biochemistry.